Gilead Sciences announced on March 15, 2024, that its Phase 3 clinical trial for the antibody-drug conjugate Trodelvy did not meet its primary endpoint. The trial...
The World Health Organization (WHO) has officially recommended Gilead Sciences’ newly approved HIV pre-exposure prophylaxis (PrEP) medication, Yeztugo (lenacapavir). This endorsement follows its approval by the...